HF

Helen Fisher

Paradigm Biopharmaceuticals Limited | Non-Executive Director
Ms Fisher is Managing Director and CEO of Bio Capital Impact Fund (BCIF). Prior to establishing BCIF, Helen was a partner of Deloitte for over 10 years and led Deloitte's Life Sciences industry practice in Australia for five years, having had many years of experience in the Life Sciences and Health Care industry. She also specialized in Financial Services, servicing some of the Australian banks and funds and has been involved in setting up several international funds, as well as advised on several M&A deals. Helen provided strategic advice to publicly listed multinational companies and has experience with capital raisings, licensing deals, demergers, implementing offshore expansions, IP management and location, and supply chain management. She is Chair of the Risk Management Committee and member of the Sustainability Committee.

Companies and Roles

Company
Title
Tenure
Since
PAR
Paradigm Biopharmaceuticals Limited
  • Non-Executive Director
3yrs, 3mthFeb 2021
CXL
Calix Limited
  • Non-Executive Director
3yrs, 8mthSep 2020

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
PAR
Paradigm Biopharmaceuticals Limited
30/11/2310,20411,225766N/A
CXL
Calix Limited
30/06/23N/A16,120N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
PAR
Paradigm Biopharmaceuticals Limited
30/11/23
Issued
1,021$0.429$438Rights issue
PAR
Paradigm Biopharmaceuticals Limited
30/11/23
Issued
766$0.389$298Rights issue
PAR
Paradigm Biopharmaceuticals Limited
18/05/23
Buy
10,204$0.982$10,020On-market trade
CXL
Calix Limited
17/11/22
Buy
7,076$4.240$30,002Participation in share purchase plan
CXL
Calix Limited
06/10/21
Buy
2,052$4.800$9,850On-market trade